<DOC>
	<DOCNO>NCT00478452</DOCNO>
	<brief_summary>This randomized Phase I/II study design assess induction anti-tumor immune response ; effect cyclophosphamide vaccine ; ass safety subject advanced ovarian cancer primary serous peritoneal cancer give multivalent DC vaccine , without single dose cyclophosphamide . Potential benefit may range direct benefit study participant stimulation subject 's immune system attack ovarian cancer prevent relapse .</brief_summary>
	<brief_title>Dendritic Cell Vaccine High Risk Ovarian Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>The following condition must meet patient may enrol study . Patients age 18 year age old . Disease Criteria . Patients eligible : If clinical evidence disease present diagnosis stage III IV disease completion primary surgery chemotherapy , , clinical evidence disease present completion chemotherapy disease recurrence diagnose progressionfree interval least 2 year , patient initial stage.or primary peritoneal carcinoma . Complete clinical response = evidence tumor lesion show abdominal CT scan MRI , chest Xray , CA 125 level ≤ 35 UI/mL . Time completion Chemotherapy 6 month last dose initial diagnosis . HLAA2 positive ( must type molecular method ; A2 alleles eligible ) . Patients adequate organ function measure : Hematopoietic : WBC least 3000/mm3 ; platelet least 100,000/mm3 , hemoglobin least 10.0 g/dL ( may transfuse ) . Cardiac : Asymptomatic , symptomatic , leave ventricular ejection fraction rest must ≥50 % within normal range institution . A cardiology clearance require LV ejection fraction &lt; 50 % . Hepatic : SGOT within 2x normal range total bilirubin ≤ 2.0 mg/dL . Renal : Serum creatinine ≤2.0 mg/dL Adequate performance status &gt; 80 % ( Karnofsky ) ECOG 02 Written inform consent conform institutional guideline . Life expectancy &gt; 6 month absence coexist medical problem would preclude participation judgment principal investigator . Any one following condition eliminate patient participate protocol . Prior malignancy ( except basal cell squamous cell skin cancer ) within past five year . Presence active Central Nervous System disease . Serious systemic disease . Active bacterial , viral fungal infection . Chemotherapy , biologic therapy radiation therapy le 4 week prior study entry . History active autoimmunity immunosuppression . Use immunosuppressive drug within 4 week prior study entry anticipate use immunosuppressive agent . Patients tumor low malignant potential ( borderline tumor ) eligible . Seropositivity HIV , HTLV1 , HTLV2 . Prior Influenza vaccination current vaccine exclude patient receive protocolspecified influenza vaccine exclude participation aspects protocol . Each year 's vaccine supply generally become available October . Patients history serious hypersensitivity egg , previous influenza vaccine component , receive influenza vaccine , may continue participate aspect protocol . Patients history serious hypersensitivity Prevnar vaccine , component , diptheria toxoid receive Prevnar vaccine , may continue participate aspect protocol . Pregnant breast feeding subject .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>